News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
Views & Analysis Medical Affairs – the heart of a data-driven, patient-centri... Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in recent years, and how the new Medical Affairs Professional Society (MAPS) wi
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Nissan stays in UK - but will Japanese pharma? Japanese R&D investment could follow EMA out of UK - experts.
News German pricing rules hit Eisai's Halaven Drug has "no additional benefit" in metastatic liposarcoma, says IQWiG.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
